Skip to main content
Equibles
KAYS logo

KAYS · Kaya Holdings, Inc.

Track KAYS — free

Use KAYS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research KAYS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.00 At close · Nov 12
Rebalance outlook locked
Going-concern doubt — flagged Nov 20, 2025

Substantial doubt about the company's ability to continue as a going concern.

“These matters raise substantial doubt about the Company's ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of this material uncertainty.”
View the 10-Q filed Nov 20, 2025
Market Cap
$892,374
Shares
686.44M
Volume · Nov 12 2627 Avg daily vol (3M) 5336

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.00 Open$0.00 Day$0.00–0.00 52W close$0.00–0.05 Avg vol 30d7K Short int6K · 0.0% of shares · 1.0d Short vol5% DataJan 2020–Nov 2026 Filing10-Q · Nov 20

Latest documents

2026
2025
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
−$1,318
Trailing 12 months
Net income (TTM)
−$11.74M
Trailing 12 months
Revenue growth YoY
+80.3%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$553,967
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+507.6%
Year over year · more shares
Price change (1Y)
-97.4%
Trailing year
Short interest
—
Latest settlement
View all 125 metrics

Quarterly results

Revenue Net income Net loss
▼71.8% $55,116 −$732,768 '23 Q2 ▼65.9% $59,011 $2.03M '23 Q3 ▼73.6% $33,922 $241,681 '23 Q4* ▼41.9% $28,009 −$1.08M '24 Q1 ▼94.9% $3,000 −$2.46M '24 Q3 ▼74.8% $7,052 −$1.64M '25 Q1 · $10,097 −$2.58M '25 Q2 LATEST ▲80.3% $5,408 −$8.58M '25 Q3

* Q4 derived as the full year minus Q1 to Q3.

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Sell Momentum Weak Sentiment Bearish Fundamentals Poor Quant / Vol Very High
Market backdrop VIX 18.7 · elevated Equity put/call 0.72
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −95%
below
Price vs 50-day avg −75%
below
RSI (14) 47
neutral
MACD trend Positive
52-week position 3%
near low
Momentum
relative strength
Weak
1-month return +1200%
trailing
6-month return −96%
trailing
YTD return −97%
this year
Relative strength −98%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow Flat
0% holders QoQ
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
0.00% of shares out · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
1 holders — 13F breadth
Fundamentals
Poor
Revenue growth −96%
Y/Y
Gross margin -5%
contracting
EPS growth −800%
Y/Y
Free cash flow $-858.0K
Balance sheet $57.5K
net debt
Quant / Vol
risk profile
Very High
Volatility 1716%
annualized · 1-yr
Max drawdown −100%
past year
ATR 161.5%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
3 · 2 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−95% Bearish
Price vs 50-day avg
−75% Bearish
RSI (14)
47 Neutral
MACD trend
Positive Bullish
52-week position
3% Bearish
Market signals — smart money & positioning
Bearish · 1 of 6
Trend (MA cross) No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow Flat
0% holders QoQ
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
0.00% of shares out · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
1 holders — 13F breadth
Price context
position in its 52-week range
Range low $0 Now $0 · 3% Range high $0
vs 200-day avg -95% vs 50-day avg -75%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
KAYS
Kaya Holdings, Inc.
this stock
$892,374 -96.7% -96.4% — 0.0%
TAK
Takeda Pharmaceutical Co Ltd
 $67.48B +35.5% — — 0.1%
GALDY
Galderma Group AG
 $54.01B +11.7% — — 0.0%
TEVA
Teva Pharmaceutical Industries Ltd
 $50.93B +39.9% +4.3% 99.2 2.4%
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
 $40.66B — — — 0.1%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders
Holders
1
% held
0.0%
Net QoQ
0 sh
Top holder
Ethos Financial Group, LLC
Held Float
View
Short & Settlement
Short Interest Rising
Shares short
6.5K
Days to cover
1.0d
Change
+6.5K sh
View
Short Volume
Short vol %
5%
As of
Sep 9, 2026
Short Total
View
Fails to Deliver
FTD shares
133
Value
$4
As of
Apr 16, 2026
View
Off-Exchange
Off-exchange %
100.0%
Week of
Oct 5, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$7.1K
Net income (FY)
$-2.1M
EPS diluted
$-0.07
View
Filings
SEC Filings
Latest
NT 10-K
Filed
Mar 30, 2026
This year
1
View
Exempt Offerings
Offering
$765.0K
Filed
Feb 15, 2024
View

Performance

5D 20D 120D MTD YTD
KAYS +0.0% +1200.0% -96.4% +0.0% -96.7%
SPY +3.3% -1.9% +1.5% +0.2% +11.0%
vs SPY -3.3% +1201.9% -97.9% -0.2% -107.7%
Key facts CIK 1530746 CUSIP 486567209 Visit website